Problem is there is so much risk and
uncertainty in the market right now.
«There are a lot of negative news and
uncertainty in the market right now about bitcoin,» Aroomoogan said.
Not exact matches
Certain matters discussed
in this news release are forward - looking statements that involve a number of risks and
uncertainties including, but not limited to, doubts about the Company's ability to continue as a going concern, the need to obtain additional funding, risks
in product development plans and schedules, rapid technological change, changes and delays
in product approval and introduction, customer acceptance of new products, the impact of competitive products and pricing,
market acceptance, the lengthy sales cycle, proprietary
rights of the Company and its competitors, risk of operations
in Israel, government regulations, dependence on third parties to manufacture products, general economic conditions and other risk factors detailed
in the Company's filings with the United States Securities and Exchange Commission.
Passed amidst bitter partisan division and an ambivalent public... the
right depends on private actors, private health insurance companies, and willing states to administer and participate
in a newly transparent, competitive, and streamlined private health insurance
market, while these same actors hesitate to invest
in the infrastructure of this
market due to
uncertainty from legal and political challenges to the ACA.
Actual results and the timing of events could differ materially from those anticipated
in the forward - looking statements due to these risks and
uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy
in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and
uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and
uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property
rights, and operate without infringing on the intellectual property
rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources;
market competition; changes
in economic and business conditions; and other factors discussed under the caption «Risk Factors»
in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.
Such risks,
uncertainties and other factors include, without limitation: (1) the effect of economic conditions
in the industries and
markets in which United Technologies and Rockwell Collins operate
in the U.S. and globally and any changes therein, including financial
market conditions, fluctuations
in commodity prices, interest rates and foreign currency exchange rates, levels of end
market demand
in construction and
in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges
in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies
in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including
in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit
market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including
market conditions and the level of other investing activities and uses of cash, including
in connection with the proposed acquisition of Rockwell; (7) delays and disruption
in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes
in political conditions
in the U.S. and other countries
in which United Technologies and Rockwell Collins operate, including the effect of changes
in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general
market conditions, global trade policies and currency exchange rates
in the near term and beyond; (16) the effect of changes
in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations
in the U.S. and other countries
in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result
in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a
right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including
in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the
market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted
in their operation of their businesses while the merger agreement is
in effect; (21) risks relating to the value of the United Technologies» shares to be issued
in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.
And
right now — with
uncertainty rife
in economies and governments all over the globe — is a perfect time to play the options game as the
markets experience wild mood swings.
Desjardins Capital
Markets analyst Benoit Poirier wrote
in a note earlier this month that despite
uncertainty, Transat's hotel strategy «remains the
right one for unlocking shareholder value.»
However, they are expected to face stiff competition from both Manchester City and Tottenham, with the latter potentially
in the
market for a new
right - back given the
uncertainty surrounding Kyle Walker's future heading into the summer transfer window.
Any statements contained
in this press release that relate to future plans, events or performance are forward - looking statements that involve risks and
uncertainties including, but not limited to, those relating to technology and product development,
market acceptance, government regulation and regulatory approval processes, intellectual property
rights and litigation, dependence on strategic partners, ability to obtain financing, competitive products and other risks identified
in deCODE's filings with the Securities and Exchange Commission.
These risks and
uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships,
uncertainty regarding potential future deterioration
in the
market for auction rate securities which could result
in additional permanent impairment charges, our ability to develop and
market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes,
market acceptance, our ability to obtain and protect intellectual property
rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified
in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified
in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time
in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.
These risks and
uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, our ability to develop and
market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes,
market acceptance, our ability to obtain and protect intellectual property
rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified
in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified
in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time
in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.
These risks and
uncertainties include, among others, those relating to technology and product development, integration of acquired businesses,
market acceptance, government regulation and regulatory approval processes, intellectual property
rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified
in deCODE's filings with the Securities and Exchange Commission.
These risks and
uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the outcome of the review of the continued listing of our common stock on The Nasdaq Stock
Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form
Market, our ability to develop and
market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form
market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes,
market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form
market acceptance, our ability to obtain and protect intellectual property
rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified
in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified
in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time
in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.
The election of Donald Trump
in the US, Britain's vote to leave the European Union and the rise of
right - wing nationalist parties across Europe signal a sharp shift away from the political and economic liberalism that have underpinned Western policy for decades, sowing widespread
uncertainty and threatening to slow the integration of global
markets with new curbs on the free movement of both people and products.
Municipal bonds can be significantly affected by political or economic changes as well as
uncertainties in the municipal
market related to taxation, legislative changes or the
rights of municipal security holders, including
in connection with an issuer insolvency.
Larry Horn: Yes,
in view of the marketplace
uncertainties regarding patent licensing needs for such technologies, there have been expressions of interest from the
market urging us to facilitate formation of licenses that would address the
market's need for a convenient one - stop marketplace alternative to negotiating separate licenses with individual patent holders
in accessing essential patent
rights for VP8 as well as other codecs, and we are looking into the prospects of doing so.
There's still a lot of
uncertainty in the cryptocurreny
markets right now if the technical analysis are to be believed which are expecting a breakout
in the coming week.
«There's so much negativity and
uncertainty right now
in the job
market,» says author and leading Career Coach Sherri Thomas, «that I wanted to publish positive success stories.
I would love to win a copy — our house is on the
market, my husband just retired from the Air Force and is looking for a job — lots of
uncertainties in our future, so I could use some simplicity
right now!